C4 Therapeutics (CCCC) Free Cash Flow Growth (1y) (2020 - 2026)
C4 Therapeutics (CCCC) Free Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | 137.65% |
| 10 | C4 Therapeutics | 441.26 Mn | 205.59 Mn | - | 9.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.92% |
| Dec 31, 2025 | -26.77% |
| Sep 30, 2025 | -27.74% |
| Jun 30, 2025 | -145.48% |
| Mar 31, 2025 | -83.71% |
| Dec 31, 2024 | 25.81% |
| Sep 30, 2024 | 22.37% |
| Jun 30, 2024 | 74.24% |
| Mar 31, 2024 | 46.26% |
| Dec 31, 2023 | 21.07% |
| Sep 30, 2023 | 0.06% |
| Jun 30, 2023 | 14.81% |
| Mar 31, 2023 | -25.95% |
| Dec 31, 2022 | -19.27% |
| Sep 30, 2022 | -82.23% |
| Jun 30, 2022 | -23.18% |
| Mar 31, 2022 | -4.33% |
| Dec 31, 2021 | -17.30% |
| Sep 30, 2021 | -16.61% |
| Jun 30, 2021 | -26.39% |